SAGE Therapeutics (SAGE) Stock Forecast & Price Target

Compare

933 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SAGE Analyst Ratings

Hold

2 Buy

11 Hold

1 Sell

Based on 14 analysts giving stock ratings to

SAGE

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SAGE Stock 12 Month Forecast

Average Price Target

$8.75

▲(34.00%Upside)

Based on 14 Wall Street analysts offering 12 month price targets for SAGE Therapeutics in the last 3 months. The average price target is $8.75 with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 34.00% change from the last price of $6.53.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","11":"$11","18":"$18","7.5":"$7.5","14.5":"$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.5,11,14.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.48,7.827692307692308,8.175384615384615,8.523076923076923,8.87076923076923,9.218461538461538,9.566153846153846,9.913846153846155,10.26153846153846,10.60923076923077,10.956923076923076,11.304615384615385,11.652307692307692,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.48,7.577692307692308,7.6753846153846155,7.773076923076923,7.870769230769231,7.968461538461539,8.066153846153846,8.163846153846155,8.261538461538462,8.35923076923077,8.456923076923077,8.554615384615385,8.652307692307692,{"y":8.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.48,7.28923076923077,7.098461538461539,6.907692307692308,6.716923076923077,6.526153846153846,6.335384615384616,6.144615384615385,5.953846153846154,5.763076923076923,5.572307692307692,5.381538461538462,5.190769230769231,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.9,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.28,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.11,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.76,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$12.00

Average Price Target$8.75

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tazeen AhmadBank of America Securities

Bank of America Securities

Sell

-23.43%

Downside

Reiterated

05/19/25

Bank of America Securities Sticks to Their Sell Rating for SAGE Therapeutics (SAGE)

Anupam RamaJ.P. Morgan

J.P. Morgan

$9→$11

Hold

68.45%

Upside

Reiterated

05/06/25

J.P. Morgan Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

Joon LeeTruist Financial

Truist Financial

―

Hold

―

Reiterated

05/05/25

SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$12

Hold

83.77%

Upside

Reiterated

04/30/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), SAGE Therapeutics (NASDAQ: SAGE) and Repligen (NASDAQ: RGEN)

Ami FadiaNeedham

Needham

―

Hold

―

Reiterated

04/30/25

Cautious Hold Rating on SAGE Therapeutics Amid Uncertain Growth Prospects

Laura ChicoWedbush

Wedbush

Hold

-8.12%

Downside

Reiterated

04/30/25

Wedbush Remains a Hold on SAGE Therapeutics (SAGE)

David AmsellemPiper Sandler

Piper Sandler

Buy

37.83%

Upside

Reiterated

04/30/25

Piper Sandler Sticks to Their Buy Rating for SAGE Therapeutics (SAGE)

George FarmerScotiabank

Scotiabank

$12

Buy

83.77%

Upside

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE) and BridgeBio Pharma (NASDAQ: BBIO)

Ritu BaralTD Cowen

TD Cowen

Hold

37.83%

Upside

Reiterated

04/29/25

Cautious Hold Rating on SAGE Therapeutics Amid Financial Pressures and Strategic Uncertainties

Marc GoodmanLeerink Partners

Leerink Partners

Hold

22.51%

Upside

Reiterated

04/29/25

SAGE Therapeutics: Hold Rating Maintained Amid Steady Growth and Strategic Uncertainties

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

Hold

22.51%

Upside

Reiterated

04/29/25

SAGE Therapeutics: Hold Rating Amid Uncertainty in Sales Growth and Strategic Developments

Brian AbrahamsRBC Capital

RBC Capital

Hold

7.20%

Upside

Reiterated

04/29/25

Analysts Conflicted on These Healthcare Names: Universal Health (NYSE: UHS), SAGE Therapeutics (NASDAQ: SAGE) and Henry Schein (NASDAQ: HSIC)

Uy EarMizuho Securities

Mizuho Securities

Hold

37.83%

Upside

Reiterated

04/29/25

SAGE Therapeutics (SAGE) Gets a Hold from Mizuho Securities

Vikram PurohitMorgan Stanley

Morgan Stanley

Hold

37.83%

Upside

Reiterated

04/21/25

Morgan Stanley Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

Joel BeattyRobert W. Baird

Robert W. Baird

$9→$7

Hold

7.20%

Upside

Reiterated

02/12/25

Sage Therapeutics price target lowered to $7 from $9 at BairdSage Therapeutics price target lowered to $7 from $9 at Baird

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tazeen AhmadBank of America Securities

Bank of America Securities

Sell

-23.43%

Downside

Reiterated

05/19/25

Bank of America Securities Sticks to Their Sell Rating for SAGE Therapeutics (SAGE)

Anupam RamaJ.P. Morgan

J.P. Morgan

$9→$11

Hold

68.45%

Upside

Reiterated

05/06/25

J.P. Morgan Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

Joon LeeTruist Financial

Truist Financial

―

Hold

―

Reiterated

05/05/25

SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$12

Hold

83.77%

Upside

Reiterated

04/30/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), SAGE Therapeutics (NASDAQ: SAGE) and Repligen (NASDAQ: RGEN)

Ami FadiaNeedham

Needham

―

Hold

―

Reiterated

04/30/25

Cautious Hold Rating on SAGE Therapeutics Amid Uncertain Growth Prospects

Laura ChicoWedbush

Wedbush

Hold

-8.12%

Downside

Reiterated

04/30/25

Wedbush Remains a Hold on SAGE Therapeutics (SAGE)

David AmsellemPiper Sandler

Piper Sandler

Buy

37.83%

Upside

Reiterated

04/30/25

Piper Sandler Sticks to Their Buy Rating for SAGE Therapeutics (SAGE)

George FarmerScotiabank

Scotiabank

$12

Buy

83.77%

Upside

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE) and BridgeBio Pharma (NASDAQ: BBIO)

Ritu BaralTD Cowen

TD Cowen

Hold

37.83%

Upside

Reiterated

04/29/25

Cautious Hold Rating on SAGE Therapeutics Amid Financial Pressures and Strategic Uncertainties

Marc GoodmanLeerink Partners

Leerink Partners

Hold

22.51%

Upside

Reiterated

04/29/25

SAGE Therapeutics: Hold Rating Maintained Amid Steady Growth and Strategic Uncertainties

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

Hold

22.51%

Upside

Reiterated

04/29/25

SAGE Therapeutics: Hold Rating Amid Uncertainty in Sales Growth and Strategic Developments

Brian AbrahamsRBC Capital

RBC Capital

Hold

7.20%

Upside

Reiterated

04/29/25

Analysts Conflicted on These Healthcare Names: Universal Health (NYSE: UHS), SAGE Therapeutics (NASDAQ: SAGE) and Henry Schein (NASDAQ: HSIC)

Uy EarMizuho Securities

Mizuho Securities

Hold

37.83%

Upside

Reiterated

04/29/25

SAGE Therapeutics (SAGE) Gets a Hold from Mizuho Securities

Vikram PurohitMorgan Stanley

Morgan Stanley

Hold

37.83%

Upside

Reiterated

04/21/25

Morgan Stanley Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

Joel BeattyRobert W. Baird

Robert W. Baird

$9→$7

Hold

7.20%

Upside

Reiterated

02/12/25

Sage Therapeutics price target lowered to $7 from $9 at BairdSage Therapeutics price target lowered to $7 from $9 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering SAGE Therapeutics

1 Month

xxx

Success Rate

12/20 ratings generated profit

Average Return

+0.27%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +0.27% per trade.

3 Months

xxx

Success Rate

14/20 ratings generated profit

Average Return

+2.60%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +2.60% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

10/20 ratings generated profit

Average Return

-5.95%

reiterated a sell rating 17 days ago

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -5.95% per trade.

2 Years

xxx

Success Rate

7/20 ratings generated profit

Average Return

-19.85%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 35.00% of your transactions generating a profit, with an average return of -19.85% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SAGE Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SAGE has received 2 Buy Ratings, 14 Hold Ratings, and 2 Sell Ratings. SAGE average Analyst price target in the past 3 months is 8.75.

Each month's total comprises the sum of three months' worth of ratings.

SAGE Financial Forecast

SAGE Earnings Forecast

Next quarter’s earnings estimate for SAGE is -$0.95 with a range of -$1.07 to -$0.80. The previous quarter’s EPS was -$1.01. SAGE beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year SAGE has Outperformed its overall industry.

SAGE Sales Forecast

Next quarter’s sales forecast for SAGE is $16.77M with a range of $15.00M to $19.60M. The previous quarter’s sales results were $14.06M. SAGE beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year SAGE has Outperformed its overall industry.

SAGE Stock Forecast FAQ

What is SAGE’s average 12-month price target, according to analysts?

Based on analyst ratings, SAGE Therapeutics, Inc. (US)’s 12-month average price target is 8.75.

What is SAGE’s upside potential, based on the analysts’ average price target?

SAGE Therapeutics, Inc. (US) has 34.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SAGE a Buy, Sell or Hold?

SAGE Therapeutics, Inc. (US) has a consensus rating of Hold which is based on 2 buy ratings, 11 hold ratings and 1 sell ratings.

What is SAGE Therapeutics, Inc. (US)’s price target?

The average price target for SAGE Therapeutics, Inc. (US) is 8.75. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $5.00. The average price target represents 34.00% Increase from the current price of $6.53.

What do analysts say about SAGE Therapeutics, Inc. (US)?

SAGE Therapeutics, Inc. (US)’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of SAGE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

SAGE Therapeutics (SAGE) Stock Forecast & Price Target

SAGE Analyst Ratings

SAGE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering SAGE Therapeutics

SAGE Analyst Recommendation Trends

SAGE Financial Forecast

SAGE Earnings Forecast

SAGE Sales Forecast

SAGE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts